Compare EMBJ & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBJ | DVA |
|---|---|---|
| Founded | 1969 | 1994 |
| Country | Brazil | United States |
| Employees | 25037 | N/A |
| Industry | Aerospace | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 13.5B |
| IPO Year | N/A | 2003 |
| Metric | EMBJ | DVA |
|---|---|---|
| Price | $64.11 | $234.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | $84.00 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.2M | 688.9K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.87 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | N/A | $3.85 |
| Revenue Next Year | $13.60 | $3.07 |
| P/E Ratio | $159.30 | ★ $81.76 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $53.56 | $101.00 |
| 52 Week High | $80.75 | $236.51 |
| Indicator | EMBJ | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 61.28 | 84.47 |
| Support Level | $60.48 | $145.58 |
| Resistance Level | $65.81 | N/A |
| Average True Range (ATR) | 1.78 | 6.00 |
| MACD | 0.54 | 1.59 |
| Stochastic Oscillator | 92.45 | 95.07 |
Embraer SA based in Sao Paulo, Brazil, manufacturer of jets. Its focus is to achieve customer satisfaction with and services addressing the commercial airline, executive jets, and defense and security markets. It has developed a customer-centric technology-driven portfolio of commercial aviation products and services that allows it to build long-term relationships with clients in the commercial aviation, executive jets, and defense and security markets. It operates through the various segments namely Commercial Aviation, Defense and Security, Executive Aviation, Service and Support, and Other Segments. The company generates maximum revenue from the Commercial Aviation segment. Geographically, the company operates in Brazil, Europe, Asia Pacific, North America, and Others.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.